Agrawal Vijit, Shrivastava Tarani Prakash, Adusumilli Pramod Kumar, Vivekanandan Kalaiselvan, Thota Prasad, Bhushan Shashi
National Coordination Centre, Pharmacovigilance Programme of India, Indian Pharmacopoeia Commission, MoHFW, GoI, Ghaziabad, Uttar Pradesh, India.
Research Scholar, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, Government of NCT, New Delhi, India.
Perspect Clin Res. 2019 Jul-Sep;10(3):140-144. doi: 10.4103/picr.PICR_29_18.
Misuse of antimicrobials has become one of the grave concerns of public health. In last two decades, this has been largely contributing in the emergence of antimicrobial resistance (AMR) among all the pathogens. A 2013 report of Centres for Disease Control and Prevention, USA figured that at least 2 million people get an antibiotic-resistant infection every year and as many as 23,000 people lost their life. A multi-country survey in Southeast Asia region conducted by World Health Organization (WHO) in 2015, identified several gaps in knowledge and awareness about the optimal use of antimicrobials and AMR. Following this, the Ministry of Health and Family Welfare (MoHFW), Government of India, developed National Action Plan in the year 2017 to combat AMR. Pharmacovigilance Programme of India (PvPI) being a flagship programme of MoHFW holds the responsibility of ensuring safety of medicines used by India population and has recently identified AMR as one of the strategic priorities. This article intends to provide insights of the recent attempts and deliberate efforts made by PvPI in the containment of AMR in India and it also intends to sensitize healthcare fraternity on restricting AMR in public interest.
抗菌药物的滥用已成为公共卫生领域的重大关切之一。在过去二十年中，这在很大程度上促成了所有病原体中抗菌药物耐药性（AMR）的出现。美国疾病控制与预防中心2013年的一份报告指出，每年至少有200万人感染耐药菌，多达23000人丧生。世界卫生组织（WHO）2015年在东南亚地区进行的一项多国调查，发现了在抗菌药物和AMR最佳使用的知识与意识方面存在若干差距。在此之后，印度政府卫生与家庭福利部（MoHFW）于2017年制定了应对AMR的国家行动计划。印度药物警戒计划（PvPI）作为MoHFW的一项旗舰计划，肩负着确保印度民众用药安全的责任，并且最近已将AMR确定为战略重点之一。本文旨在深入探讨PvPI最近在印度遏制AMR方面所做的尝试和刻意努力，同时也旨在提高医疗界对为公共利益限制AMR的认识。
